Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 568: Nivolumab + Ipilimumab in First-Line NSCLC
NCT02659059Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Started Feb 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02659059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02659059.